Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes

References

• Zur Hausen H. Papillomavirus infections—a major cause of human cancers. Biochim Biophys Acta 1996;1288: F55–78.
   PubMed Web of Science ®Google Scholar
• Walboomers J, Jacobs M, Manos M, Bosch FX, Kummer JA, Shah KV, . Human papilloma virus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12–9.
   PubMed Web of Science ®Google Scholar
• Clifford G, Franceschi S, Diaz M, Munoz N, Villa L. HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006;24(S3):26–34.
   Google Scholar
• Iwasawa A, Nieminen P, Lehtinen M, Paavonen J. Human papillomavirus DNA in uterine cervix squamous cell carcinoma and adenocarcinoma detected by polymerase chain reaction. Cancer 1996;77:2275–9.
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Paavonen J. Effectiveness of preventive human papillomavirus vaccination. Int J STD AIDS 2003;14:787–92.
   PubMed Web of Science ®Google Scholar
• Thomas K, Hughes J, Kuypers J, Kiviat N, Lee S, Adam D, . Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis 2000;182:1097–102.
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Kaasila M, Pasanen K, Patama T, Palmroth J, Laukkanen P, . Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s. Int J Cancer 2006;119:2612–9.
   PubMed Web of Science ®Google Scholar
• Fife K, Cramer H, Schroeder J, Brown D. Detection of multiple human papillomavirus types in the lower genital tract correlates with cervical dysplasia. J Med Virol 2001;64:550–9.
   PubMed Web of Science ®Google Scholar
• Trottier H, Mahmud S, Costa MC, Sobrinho JP, Duarte-Franco E, Rohan TE, . Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2006;5:1274–80.
   Google Scholar
• Luostarinen T, Geijerstamm V, Bjorge T, Eklund C, Hakama M, Hakulinen T, . No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11. Int J Cancer 1999;80:818–22.
   PubMed Web of Science ®Google Scholar
• Luostarinen T, Lehtinen M, Bjorge T, Abeler V, Hakama M, Hallmans G, . Joint effects of different human papillomavirus and Chlamydia trachomatis infections and risk of squamous cell carcinoma of the cervix uteri. Eur J Cancer 2004;40:1058–67.
   PubMed Web of Science ®Google Scholar
• Syrjänen K. Natural history of cervical HPV infections and CIN. In: Syrjänen K, Syrjänen S, editors. Papillomavirus infections in human pathology. New York: J. Wiley & Sons; 2000. pp. 142–66.
   Google Scholar
• Simen-Kapeu A, Kataja V, Yliskoski M, Syrjänen K, Dillner J, Koskela P, . Smoking impairs human papillomavirus (HPV) type 16 and 18 capsids antibody response following natural HPV infections. Scand J Infect Dis 2008;40:745–51.
   PubMed Web of Science ®Google Scholar
• Dillner J, Kallings I, Brihmer C, Sikström B, Koskela P, Lehtinen M, . Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis 1996;173:1394–8.
   PubMed Web of Science ®Google Scholar
• Kjellberg L, Wang Z, Wiklund F, Edlund K, Ångström T, Lenner P, . Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case–control study. J Gen Virol 1999;80:391–8.
   PubMed Web of Science ®Google Scholar
• af Geijersstam V, Kibur M, Wang Z, Koskela P, Pukkala E, Schiller J, . Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis 1998;177:1710–4.
   PubMed Web of Science ®Google Scholar
• Dillner J. The serological response to papillomaviruses. Semin Cancer Biol 1999;9:423–30.
   PubMed Web of Science ®Google Scholar
• Liaw KL, Hildesheim A, Burk RD, Gravitt P, Wacholder S, Manos MM, . A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001;183:8–15.
   PubMed Web of Science ®Google Scholar
• Rousseau MC, Pereira JS, Prado JC, Villa LL, Rohan TE, Franco EL. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis 2001;184:1508–17.
   PubMed Web of Science ®Google Scholar
• Viscidi RP, Schiffman M, Hildesheim A, Herrero R, Castle PE, Bratti MC, . Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004;13:324–7.
   PubMed Web of Science ®Google Scholar
• Ho GY, Studentsov Y, Hall CB, Bierman R, Beardsley L, Lempa M, . Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis 2002;186:737–42.
   PubMed Web of Science ®Google Scholar
• Kaasila M, Koskela P, Kirnbauer R, Pukkala E, Surcel HM, Lehtinen M. Dynamics of co-infections with natural human papillomavirus types 11, 16, 18 and 31 in fertile-aged female population dynamics of serologically identified coinfections with human papillomavirus type 11, 16, 18 and 31 in fertile-aged finnish women. Int J Cancer 2009;125:2166–72.
   PubMed Web of Science ®Google Scholar
• Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, . The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis 2009;199:926–35.
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud D, Salmeron J, Wheeler CM, Chow SN, Apter D, . Efficacy of human papillomavirus (HPV) 16/18 AS04 adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301–14.
   PubMed Web of Science ®Google Scholar
• Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423–8.
   PubMed Web of Science ®Google Scholar
• Haavio-Mannila E, Kontula O, Kuusi E. Trends in sexual life. Working papers E 10/2001. Helsinki: The Population Research Institute; 2001.
   Google Scholar
• Ault K, Villa L, Perez G, Kjaer S, Lehtinen M, Paavonen J, ; Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369:1861–8.
   PubMed Web of Science ®Google Scholar
• Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, . Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161–70.
   PubMed Web of Science ®Google Scholar